TAK
Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Co Ltd ADR historical holders
total: 3
Pzena Investment Management Takeda Pharmaceutical Co Ltd ADR transactions over time
- Total transactions:
- 3
- New positions:
- 1
- Added:
- 2
- Held since:
- 2025 Q4
- Held for:
- 3 quarters
- Latest activity:
- 2026 Q2
Richard Pzena has been an institutional investor in Takeda Pharmaceutical Co Ltd ADR (TAK) since 2025 Q4. According to 2026 Q2 report, Richard Pzena holds 37,820 shares with a market value of roughly $606.25K representing 0.00% of their equity portfolio. The fund/company first acquired TAK in 2025 Q4, initially purchasing 20,627 shares. Since the initial investment, Pzena Investment Management has made 2 more transactions in this position.
Does Richard Pzena still hold TAK?
Yes, Richard Pzena continues to hold Takeda Pharmaceutical Co Ltd ADR (TAK). According to their 2026 Q2 report, they maintain a position of 37,820 shares valued at approximately $606.25K, representing 0.00% of their equity portfolio.
When did Richard Pzena first invest in TAK?
Richard Pzena first invested in Takeda Pharmaceutical Co Ltd ADR (TAK) in 2025 Q4 at the reported quarter-end price of $15.59 per share, acquiring 20,627 shares in their initial purchase.
What is Richard Pzena's average cost basis for TAK?
Based on historical transaction data, Richard Pzena's estimated cost basis for Takeda Pharmaceutical Co Ltd ADR (TAK) is approximately $16.30 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $16.30
TAK transactions history by Pzena Investment Management
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
37,820
|
$16.03
|
$606,253
|
+33.36% (+9,460)
|
+0%
|
|
2026 Q1
|
0.00%
|
28,360
|
$18.52
|
$525,231
|
+37.49% (+7,733)
|
+0%
|
|
2025 Q4
|
0.00%
|
20,627
|
$15.59
|
$321,575
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.